1. Home
  2. RLAY vs CINGW Comparison

RLAY vs CINGW Comparison

Compare RLAY & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLAY
  • CINGW
  • Stock Information
  • Founded
  • RLAY 2015
  • CINGW N/A
  • Country
  • RLAY United States
  • CINGW United States
  • Employees
  • RLAY N/A
  • CINGW 13
  • Industry
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • RLAY Health Care
  • CINGW Health Care
  • Exchange
  • RLAY Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • RLAY N/A
  • CINGW N/A
  • IPO Year
  • RLAY 2020
  • CINGW 2021
  • Fundamental
  • Price
  • RLAY $2.69
  • CINGW $0.04
  • Analyst Decision
  • RLAY Strong Buy
  • CINGW
  • Analyst Count
  • RLAY 10
  • CINGW 0
  • Target Price
  • RLAY $19.33
  • CINGW N/A
  • AVG Volume (30 Days)
  • RLAY 3.0M
  • CINGW N/A
  • Earning Date
  • RLAY 05-01-2025
  • CINGW N/A
  • Dividend Yield
  • RLAY N/A
  • CINGW N/A
  • EPS Growth
  • RLAY N/A
  • CINGW N/A
  • EPS
  • RLAY N/A
  • CINGW N/A
  • Revenue
  • RLAY $10,007,000.00
  • CINGW N/A
  • Revenue This Year
  • RLAY N/A
  • CINGW N/A
  • Revenue Next Year
  • RLAY $420.18
  • CINGW N/A
  • P/E Ratio
  • RLAY N/A
  • CINGW N/A
  • Revenue Growth
  • RLAY N/A
  • CINGW N/A
  • 52 Week Low
  • RLAY $1.78
  • CINGW N/A
  • 52 Week High
  • RLAY $10.72
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • RLAY 48.08
  • CINGW N/A
  • Support Level
  • RLAY $1.82
  • CINGW N/A
  • Resistance Level
  • RLAY $2.81
  • CINGW N/A
  • Average True Range (ATR)
  • RLAY 0.26
  • CINGW 0.00
  • MACD
  • RLAY 0.09
  • CINGW 0.00
  • Stochastic Oscillator
  • RLAY 88.41
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: